Fabtech Technologies Cleanrooms Ltd: Modular Walls, Margins, and Multibagger Whispers — Is This Pharma Infra Prince for Real?
1. At a Glance
Cleanroom crusader Fabtech went from obscure modular pharma vendor to ₹533 Cr SME stock darling in 2025. Riding on pharma infra tailwinds and order wins, it delivered ₹150 Cr revenue and ₹13 Cr PAT in FY25. Trading at a PE of 40.1 with 21% ROCE and practically no debt.
2. Introduction with Hook
Imagine if IKEA built operating theatres. Fabtech Technologies does exactly that — minus the hex keys and frustration. They build modular, regulatory-grade cleanrooms that turn dusty sheds into pharma-grade sterile temples.
The result?
130% TTM profit growth
21% ROCE, 18.2% ROE
₹85 Cr order book with Q1FY26 revenue up 32% YoY
Clean margins, clean balance sheet, cleanroom play. But how clean is the valuation?
3. Business Model (WTF Do They Even Do?)
Fabtech builds cleanrooms and modular infrastructure for:
Pharma Manufacturing
Biotech R&D
Hospitals & ICUs
Global Exports adhering to FDA, ISO, WHO-GMP norms
